Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM7YII9)

Drug Name
Dazodalibep Drug Info
Synonyms VIB4920
Indication
Disease Entry ICD 11 Status REF
Kidney transplant rejection NE84 Phase 2 [1]
Rheumatoid arthritis FA20 Phase 2 [2]
Sjogren syndrome 4A43.20 Phase 2 [3]
Cross-matching ID
TTD Drug ID
DM7YII9

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
CD40L receptor (CD40) TTN6Y9A TNR5_HUMAN Inhibitor [4]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
CD40L receptor (CD40) DTT CD40 4.629 4.991 5.53 3.385
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

ICD Disease Classification 15 Disease of the musculoskeletal system/connective tissue
Disease Class ICD-11: FA20 Rheumatoid arthritis
The Studied Tissue Synovial tissue
The Studied Disease Rheumatoid arthritis [ICD-11:FA20]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
CD40L receptor (CD40) DTT CD40 1.43E-06 0.96 4.15
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT04046549) A Phase 2a Single-arm, Prospective, Open-label Pilot Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant. U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT04163991) A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Mechanistic Insight and Dosage Optimization Study of the Efficacy and Safety of VIB4920 in Patients With Rheumatoid Arthritis (RA). U.S.National Institutes of Health.
3 ClinicalTrials.gov (NCT04129164) A Phase 2 Randomized, Double-blind, Placebo-controlled, Proof of Concept Study to Evaluate the Efficacy and Safety of VIB4920 in Subjects With Sj?gren's Syndrome (SS). U.S.National Institutes of Health.
4 The enhanced immunopharmacology of VIB4920, a novel Tn3 fusion protein and CD40L antagonist, and assessment of its safety profile in cynomolgus monkeys. Br J Pharmacol. 2020 Mar;177(5):1061-1076.